Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alpha-galactosidase A null mice.
about
Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry diseaseCase study on the pathophysiology of Fabry disease: abnormalities of cellular membranes can be reversed by substrate reduction in vitro.The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases.Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease.Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells.Differential involvement of COX1 and COX2 in the vasculopathy associated with the alpha-galactosidase A-knockout mouse.Decreased nitric oxide bioavailability in a mouse model of Fabry disease.Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect.Endothelial nitric oxide synthase uncoupling and microvascular dysfunction in the mesentery of mice deficient in α-galactosidase A.Molecular biology of atherosclerosis.Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.Mapping mechanisms and charting the time course of premature cell senescence and apoptosis: lysosomal dysfunction and ganglioside accumulation in endothelial cells.Glycosphingolipid Mediated Caveolin-1 Oligomerization.Co-administration with the pharmacological chaperone AT1001 increases recombinant human α-galactosidase A tissue uptake and improves substrate reduction in Fabry mice.
P2860
Q28748170-CDE2D06E-44E1-4018-8294-9DE0E5E65FF4Q33613449-72C8A32D-6F19-47E0-B001-409DFAD4B371Q33825097-3A31D25B-E57D-467F-B6B6-283D9CFBCB0CQ33831482-EA346791-2D09-4AB7-9F43-5339CDC738CBQ36995447-1AFF20D8-A18F-48EB-8F7E-98BA4C1DA346Q37162532-1332E177-DF42-4E22-922F-ACCD37630395Q37330561-D7CAF79E-B3E4-42B3-B135-D4257575F63FQ37347258-E0DB4676-7946-4231-ABA8-E608A7CFA5DAQ37575656-9AD3167C-0F3B-4A05-ABF1-00B58E6CD59FQ38125279-6F36C563-7747-4ABA-A70E-4B3F5CAA3AD4Q39636269-DB6745FF-33FB-4C80-8D17-31FAA4BCC944Q40069502-4C1658C0-E968-4FE5-B1A1-D5B4DF7C397EQ42148671-0004C29D-4DBF-40DA-A3FC-962C85F61250Q42238272-C3CEFAD3-F160-4BA8-B80F-1C89D3009519
P2860
Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alpha-galactosidase A null mice.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Caveolin-associated accumulati ...... pha-galactosidase A null mice.
@en
Caveolin-associated accumulati ...... pha-galactosidase A null mice.
@nl
type
label
Caveolin-associated accumulati ...... pha-galactosidase A null mice.
@en
Caveolin-associated accumulati ...... pha-galactosidase A null mice.
@nl
prefLabel
Caveolin-associated accumulati ...... pha-galactosidase A null mice.
@en
Caveolin-associated accumulati ...... pha-galactosidase A null mice.
@nl
P2860
P356
P1476
Caveolin-associated accumulati ...... pha-galactosidase A null mice.
@en
P2093
James A Shayman
Liming Shu
P2860
P304
20960-20967
P356
10.1074/JBC.M702436200
P407
P577
2007-05-29T00:00:00Z